Evaluation of oxidative stress and paraoxonase phenotypes in pseudoexfoliation syndrome and pseudoexfoliation glaucoma

Clinical Laboratory

Volumn 60, Issue 1, 2014, Pages 79-86

  Can Demirdöǧen, Birsen ^a   Ceylan, Osman Melih ^b   Işikoǧlu, Semra ^c   Mumcuoǧlu, Tarkan ^b   Erel, Özcan ^c  

^a MINISTRY OF HEALTH   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Total antioxidant status; Total oxidant status; Total thiol

Indexed keywords

ARYLDIALKYLPHOSPHATASE; EXFOLIATION SYNDROME; HUMANS; OXIDATIVE STRESS;

EID: 84893928379     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.121229     Document Type: Article

References (68)

1. Lindberg JG. Clinical studies of depigmentation of the pupillary margin and transillumination of the iris in cases of senile cataract and also in normal eyes in the aged. Diss Helsingfors (Thesis) 1917.
2. Streeten BW, Li Z-Y, Wallace RN, Eagle RC, Keshgegian AA. Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophtalmol 1992;110:1757-62.
3. Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliative syndrome with increased vascular risk. Am J Ophtalmol 1997;124:684-7.
4. Citirik M, Acaroglu G, Batman C, Yildiran L, Zilelioglu O. A possible link between the pseudoexfoliation syndrome and coronary artery disease. Eye 2007;21:11-5. (Pubitemid 46061863)
5. Schlötzer-Schrehardt U, Naumann GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 2006;141:921-37.
6. Kusano C, Ferrari B. Total Antioxidant Capacity: a biomarker in biomedical and nutritional studies. Journal of Cell and Molecular Biology 2008;7(1):1-15.
7. Chung HS, Lee SJ, Chung SM, Lee MY, Bae ON, Chung JH. Generation of free radical by interaction of iron with thiols in human plasma and its possible significance. Thromb Res 2005;116:157-64.
8. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 1998;55:1747-58. (Pubitemid 28305256)
9. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Med J 2004;45:776-88. (Pubitemid 39545364)
10. Iciek M, Chwatko G, Lorenc-Koci E, Bald E, Włodek L. Plasma levels of total, free and protein bound thiols as well as sulfane sulfur in different age groups of rats. Acta Biochim Pol 2004;51(3):815-24. (Pubitemid 39296933)
11. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 2004;369(1):78-88. (Pubitemid 38161225)
12. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000;275:3957-62. (Pubitemid 30094622)
13. Josse D, Bertels C, Lockidge O, Masson P. PON1 structure. In: Costa LG, Furlong CE, editors. Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Norwell, MA: Kluwer Acad., 2002:27-52.
14. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
15. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995;96:2882-91.
16. Arrol S, Mackness MI, Durrington PN. High-density lipoprotein associated enzymes and the prevention of low-density lipoprotein oxidation. Eur J Lab Med 1996;4:33-8. (Pubitemid 27067961)
17. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein and preserves its functions. J Clin Invest 1998;101:1581-90.
18. Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-7. (Pubitemid 28335041)
19. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35. (Pubitemid 24035640)
20. Tomás M, Latorre G, Sentí M, Marrugata J. The Antioxidant Function of High Density Lipoproteins: A New Paradigm in Atherosclerosis. Rev Esp Cardiol 2004;57:557-69. (Pubitemid 38997113)
21. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671-3. (Pubitemid 17027211)
22. Aydin M, Gencer M, Cetinkaya Y, et al. PON1 55/192 polymorphism, oxidative stress, type, prognosis and severity of stroke. IUBMB Life 2006;58(3):165-72. (Pubitemid 43786042)
23. Humbert R, Adler DA, Distecke CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6. (Pubitemid 23063292)
24. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983;35:214-27. (Pubitemid 13111118)
25. Furlong CE, Cole TB, Walter BJ, et al. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol 2005;19(3):182-3. (Pubitemid 40967291)
26. Yaǧci R, Gürel A, Ersöz I, Karadaǧ R, Hepşen IF, Duman S. The activities of paraoxonase, xanthine oxidase, adenosine deaminase and the level of nitrite in pseudoexfoliation syndrome. Ophthalmic Res 2009;42(3):155-9.
27. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-9. (Pubitemid 38077161)
28. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103-11.
29. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
30. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-38. (Pubitemid 14201166)
31. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.
32. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994;233:380-5.
33. Hoeschen RJ. Oxidative stress and cardiovascular disease. Can J Cardiol 1997;13(11):1021-5. (Pubitemid 28004541)
34. Seneş M, Kazan N, Coşkun O, Zengi O, Inan L, Yücel D. Oxidative and nitrosative stress in acute ischaemic stroke. Ann Clin Biochem 2007;44(Pt 1):43-7. (Pubitemid 46168800)
35. Kaneto H, Katakami N, Kawamori D, et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007;9(3):355-66. (Pubitemid 46145981)
36. de Champlain J, Wu R, Girouard H, et al. Oxidative stress in hypertension. Clin Exp Hypertens 2004;26(7-8):593-601. (Pubitemid 40129747)
37. Beatty S, Koh H, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-34.
38. Spector A. Oxidative stress-induced cataract: mechanisms of action. FASEB J 1995;9:1173-82.
39. Augusteyn RC, Duncan G. Mechanisms of Cataract Formation in the Human Lens. London: Academic Press, 1981:71-116.
40. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001;45:265-315. (Pubitemid 32146432)
41. Sofic E, Rustembegovic A, Kroyer G, Cao G. Serum antioxidant capacity in neurological, psychiatric, renal diseases and cardiomyopathy. J Neur Transm 2002;109:711-9. (Pubitemid 34810768)
42. Kashyap MK, Yadav V, Sherawat BS, et al. Different antioxidant status, total antioxidant power and free radicals in essential hypertension. Mol Cell Biochem 2005;277:89-99. (Pubitemid 41236190)
43. Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatr 2004;16(4):200-3. (Pubitemid 39663120)
44. Akalin FA, Baltacioǧlu E, Alver A, Karabulut E. Lipid peroxidation levels and total oxidant status in serum, saliva and gingival crevicular fluid in patients with chronic periodontitis. J Clin Periodontol 2007;34(7):558-65.
45. Koliakos GG, Konstas AG, Schlötzer-Schrehardt U, Bufidis T, Georgiadis N, Ringvold A. Ascorbic acid concentration is reduced in the aqueous humor of patients with exfoliation syndrome. Am J Ophthalmol 2002;134:879-83. (Pubitemid 35425457)
46. Yimaz A, Adiguzel U, Tamer L, et al. Serum oxidant/antioxidant balance in exfoliation syndrome. Clin Exp Ophthalmol 2005;33:63-6. (Pubitemid 40330978)
47. Gartaganis SP, Patsoukis NE, Nikolopoulos DK, Georgiou CD. Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome. Eye 2007;21:1406-11. (Pubitemid 350066474)
48. Yildirim Z, Uçgun NI, Kiliç N, Gürsel E, Sepici-Dinçel A. Pseudoexfoliation syndrome and trace elements. Ann N Y Acad Sci 2007;1100:207-12. (Pubitemid 47092654)
49. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 2004;137:62-9. (Pubitemid 38045188)
50. Oshida E, Matsumoto Y, Arai K. Free radicals in the aqueous humor of patients with glaucoma. Clin Ophthalmol 2010;4:653-60.
51. Coral K, Raman R, Rathi S, et al. Plasma homocysteine and total thiol content in patients with exudative age-related macular degeneration. Eye (Lond) 2006;20(2):203-7.
52. Yilmaz FM, Yilmaz G, Erol MF, Köklü S, Yücel D. Nitric oxide, lipid peroxidation and total thiol levels in acute appendicitis. J Clin Lab Anal 2010;24(2):63-6.
53. Aldemir M, Okulu E, Neşelioǧlu S, Erel O, Ener K, Kayigil O. Evaluation of serum oxidative and antioxidative status in patients with erectile dysfunction. Andrologia 2011 Jun 30. doi: 10.1111/j.1439-0272.2011. 01174.x.
54. Mackness B, Durrington PN, Boulton AJ, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest 2002;32(4):259-64. (Pubitemid 36216591)
55. Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998;44:179-81. (Pubitemid 28042485)
56. Raiszadeh F, Solati M, Etemadi A, Azizi F. Serum paraoxonase activity before and after treatment of thryotoxicosis. Clin Endocrinol 2004;60:75-80. (Pubitemid 38183501)
57. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002;252:63-7. (Pubitemid 36056678)
58. Koliakos GG, Befani CD, Mikropoulos D, Ziakas NG, Konstas AG. Prooxidant-antioxidant balance, peroxide and catalase activity in the aqueous humour and serum of patients with exfoliation syndrome or exfoliative glaucoma. Graefes Arch Clin Exp Ophthalmol. 2008;246(10):1477-83.
59. Shih DM, Gu L, Hama S, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996;97:1630-9. (Pubitemid 26105474)
60. Navab M, Hama-Levy S, Van Lenten BJ, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997;99:2005-19. (Pubitemid 27175949)
61. Zech R, Zurcher K. Organophosphate splitting serum enzymes in different mammals. Comp Biochem Physiol 1974;48:427-33.
62. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;53:598-608. (Pubitemid 23311330)
63. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004;107:435-47. (Pubitemid 39506735)
64. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet 1996;14:334-6.
65. Mackness MI, Arrol S, Mackness B, Durrington PN. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet 1997;349:851-2. (Pubitemid 27129220)
66. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol 1998;10:1617-24. (Pubitemid 28465415)
67. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998;423:57-60. (Pubitemid 28098579)
68. Demirdogen BC, Demirkaya Ş, Türkanoǧlu A, Bek S, Arinç E, Adali O. Analysis of paraoxonase 1 (PON1) genetic polymorphisms and activities as risk factors for ischemic stroke in Turkish population. Cell Biochem Funct. 2009;27(8):558-567.